Utilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
Utilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
Plasma proteomics is a powerful approach for discovering novel protein biomarkers of drug toxicity in various disease contexts. One such biomarker in cardiovascular disease is apolipoprotein M (ApoM), which plays a crucial role in lipid metabolism and transport and is known to have both anti-inflammatory and cardioprotective effects in the body. Studying ApoM using proteomics requires various approaches to understand its expression, modifications, interactions, and functions in the proteome.
Learn about:
- Association between ApoM and heart failure outcomes
- Effects of the chemotherapeutic drug doxorubicin on ApoM levels
- How ApoM heterozygosity affects the regulation of transcription factor EB
Ali Javaheri, MD
Assistant Professor, Medicine, Cardiovascular Division
Washington University School of Medicine in St. Louis
Ali Javaheri, MD, is Assistant Professor of Medicine and Investigator in the Center for Cardiovascular Research at Washington University in St. Louis, and broadly trained in multiple disciplines. His clinical expertise and training is in advanced heart failure, a syndrome with no cure that has a worse prognosis than many cancers (5 year 50% mortality). He has led and contributed to studies that have utilized proteomic strategies to uncover the importance of novel pathways in human heart failure. These studies have highlighted the important role of apolipoprotein M (ApoM). Reduced circulating ApoM is associated with poor prognosis in heart failure. Dr. Javaheri shows the ApoM-content of isolated high-density lipoprotein correlates strongly with its sphingosine-1-phosphate content; however, adjusting for sphingosine-1-phosphate levels only partially attenuated the association between ApoM and heart failure survival. Together with Dr. Mahmoud Nasr at Harvard Medical School, Dr. Javaheri recently filed a provisional patent for nanotherapies related to ApoM. His ongoing studies on ApoM suggest significant translational potential for this pathway in heart failure.
Utilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure
A presentation by Ali Javaheri, MD
More webinars
WebinarBoutique Webinar: Multiomic Breakthroughs: Immune Monitoring for Precision Disease Detection
WebinarEvaluation of precision and correlation for the latest proteomic platforms
The field of proteomics is rapidly advancing, enabling precise measurement of thousands of proteins, particularly those in higher abundance. This webcast will explore significant differences in precision within and across the latest large-scale proteomic platforms and their intercorrelations, based on blind duplicate split assays of the leading modified aptamer-based 11K and antibody proximity ligation-based 5K platforms. Each platform exhibits distinct strengths and limitations, requiring careful consideration prior to implementation in individual studies.
WebinarScaling Proteomics: Balancing Performance and Measuring Enough Proteins
As proteomics platforms have advanced, the number of proteins measured and sample throughput have dramatically increased. However, have sacrifices or trade-offs been necessary to make these gains? To find out, Stephen Williams will analyze how the performance of proteomics platforms has changed over time, comparing precision, sensitivity and specificity as throughput increases.